Merck's Keytruda Regime Approved In Canada For Early Breast Cancer Setting

Health Canada has approved Merck & Co Inc MRK Keytruda (pembrolizumab) for adult patients with high-risk early-stage triple-negative breast cancer (TNBC) setting.
The approval covers Keytruda combined with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.
Related: EMA's Advisory Group Backs Approval For Merck's Keytruda In Various Cancer Settings.
The nod is based on Phase 3 KEYNOTE-522 trial results, demonstrating a statistically significant improvement in patients' event-free survival (EFS) and pathological complete response (pCR) rate.
Keytruda was first approved in Canada in 2015 and currently has cancer indications.
Price Action: MRK shares are up 0.07% at $86.97 during the premarket session on Monday's last check.

Momentum16.06

Growth87.86

Quality51.51

Value43.81

Short

Medium

Long